webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Val-cit-PAB-OH

  CAS No.: 159857-79-1   Cat No.: BADC-00708   Purity: 95% 4.5  

Val-cit-PAB-OH is a cleavable ADC linker commonly used in targeted therapies. It responds to lysosomal enzymes for selective payload activation in cancer cells.

Val-cit-PAB-OH

Structure of 159857-79-1

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C18H29N5O4
Molecular Weight
379.46
Shipping
-20°C (International: -20°C)
Storage
-20°C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
100 mg $188 In stock
5 g $249 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
L-valyl-N5-carbamoyl-N-[4-(hydroxymethyl)phenyl]-L-omithinamide; Val-cit-PAB; (S)-2-((S)-2-amino-3-methylbutanamido)-N-(4-(hydroxymethyl)phenyl)-5-ureidopentanamide
IUPAC Name
(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)-N-[4-(hydroxymethyl)phenyl]pentanamide
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)CO)N
InChI
InChI=1S/C18H29N5O4/c1-11(2)15(19)17(26)23-14(4-3-9-21-18(20)27)16(25)22-13-7-5-12(10-24)6-8-13/h5-8,11,14-15,24H,3-4,9-10,19H2,1-2H3,(H,22,25)(H,23,26)(H3,20,21,27)/t14-,15-/m0/s1
InChIKey
VEGGTWZUZGZKHY-GJZGRUSLSA-N
Density
1.243±0.06 g/cm3
Solubility
Soluble to ≥ 59 mg/ml in DMSO
Melting Point
715.0±60.0 °C | Condition: Press: 760 Torr
Appearance
White to off-white solid
Quantity
Grams-Kilos
Shelf Life
2 years
Shipping
-20°C (International: -20°C)
Storage
-20°C
Pictograms
Irritant
Signal Word
Warning

Val-Cit-PAB-OH is a protease-cleavable ADC linker extensively used in antibody-drug conjugate design. It contains a valine-citrulline (Val-Cit) dipeptide sequence linked to a para-aminobenzyl (PAB) self-immolative spacer, providing controlled release of ADC cytotoxins upon enzymatic cleavage. This linker design is widely adopted in ADC linker design for oncology therapeutics, as it allows selective activation of the payload in lysosomal environments while maintaining stability in systemic circulation.

In ADC payload applications, the Val-Cit sequence serves as a substrate for cathepsin B and related proteases, ensuring that the cytotoxic ADC payload is released specifically within target tumor cells. The PAB self-immolative spacer transduces enzymatic cleavage into efficient payload release, preserving antibody-antigen binding functionality. This structure enables precise control over drug-to-antibody ratios (DAR), supporting reproducible and predictable pharmacokinetic properties of ADCs.

The chemical stability of Val-Cit-PAB-OH under physiological conditions prevents premature payload detachment in plasma, while its protease sensitivity ensures effective release in the tumor microenvironment. The linker is compatible with a broad range of ADC cytotoxins, including auristatins, maytansinoids, and other potent therapeutic payloads, providing versatility in ADC design and development.

Val-Cit-PAB-OH is widely applied in ADC construction and bioconjugation workflows where controlled payload release, linker stability, and precise antibody conjugation are critical. Its combination of protease-cleavable dipeptide, self-immolative PAB spacer, and chemical robustness supports the generation of high-performance antibody-drug conjugates with optimized therapeutic efficacy and tumor specificity.

What is Val-cit-PAB-OH?

Val-cit-PAB-OH is a dipeptide-based, lysosomal enzyme-cleavable linker widely used in ADCs. The Val-Cit moiety is recognized by cathepsin B, while the PAB-OH self-immolative group enables payload release upon enzymatic cleavage within target cells.

13/2/2022

We would like to know how Val-cit-PAB-OH influences ADC drug release.

Val-cit-PAB-OH ensures controlled intracellular release of cytotoxic payloads. The Val-Cit dipeptide is selectively cleaved by lysosomal enzymes, triggering the PAB-OH self-immolative spacer to release the attached drug efficiently and specifically.

5/7/2022

Could you kindly inform us what storage conditions are recommended for Val-cit-PAB-OH?

Val-cit-PAB-OH should be kept at -20°C, protected from moisture and light. Maintaining low-temperature storage and inert conditions prevents hydrolysis and degradation of the dipeptide and PAB-OH moiety.

2/8/2019

Good morning! Could you please confirm if BOC Sciences provides supporting documentation for Val-cit-PAB-OH?

Yes, supporting documentation such as CoA, NMR, and LC-MS data are available. These files confirm the chemical identity, functional group integrity, and suitability for ADC conjugation and downstream applications.

15/8/2022

Good morning! What analytical techniques do you recommend for Val-cit-PAB-OH?

Structural verification and functional assessment of Val-cit-PAB-OH are typically conducted using NMR spectroscopy, HPLC, and LC-MS to ensure quality and readiness for bioconjugation.

22/2/2019

— Dr. Olivia Brown, Senior Researcher (UK)

Val-cit-PAB-OH delivered excellent performance in our ADC linker synthesis. Purity and handling were ideal.

2/8/2019

— Mr. David Wilson, Chemistry Scientist (USA)

Batch-to-batch consistency of Val-cit-PAB-OH allowed seamless integration into our ADC pipeline.

22/2/2019

— Dr. Michael Carter, ADC Researcher (USA)

Val-cit-PAB-OH supplied by BOC Sciences demonstrated excellent purity and stability. It performed reliably in our ADC linker synthesis, ensuring reproducible results.

15/8/2022

— Dr. Michael Carter, ADC Researcher (USA)

Val-cit-PAB-OH supplied by BOC Sciences demonstrated excellent purity and stability. It performed reliably in our ADC linker synthesis, supporting reproducible results.

13/2/2022

— Dr. Mark Taylor, Bioconjugation Specialist (Canada)

Documentation and QC reports for Val-cit-PAB-OH were thorough, aiding regulatory submissions.

— Dr. Isabella Lee, Senior Scientist (USA)

The technical team provided guidance that optimized Val-cit-PAB-OH conjugation, improving ADC yield.

5/7/2022

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Doxorubicin hydrochloride | Folate-PEG3-amine | SMPT | Fmoc-PEG4-NHS ester | Azido-PEG8-NHS ester | PEG12-Tos | Perfluorophenyl 2-(cyclooct-2-ynyloxy)acetate | Gly-Gly-Phe-OH | Daunorubicin hydrochloride | Seco-DuocarmycinDME | Val-cit-PAB-OH
Send Inquiry
Verification code
Inquiry Basket